Main Menu

ChemoCentryx, Inc.

(NASDAQ GS: CCXI)

Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of ChemoCentryx, Inc. (“ChemoCentryx”) on behalf of stockholders.  A class action complaint has been filed against ChemoCentryx.  The complaint alleges that, between November 26, 2019 and May 6, 2021, defendants misrepresented and/or failed to disclose to investors that: (i) the study design of ChemoCentryx’s Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of the drug candidate avacopan and its role in the management of ANCA-associated vasculitis; (ii) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (iii) these issues presented a substantial concern regarding the viability of ChemoCentryx’s new drug application for avacopan for the treatment of ANCA-associated vasculitis; and (iv) as a result, defendants’ public statements were materially false and misleading.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 05/16/2022


* Indicates a required field.

Back to Page